Key result
Causes of sporadic corticotroph adenomas remain unclear despite better genetic understanding of syndromic tumors.
Why the study?
The causative mechanisms involved in pituitary corticotroph tumour cell transformation and tumourigenesis remain unclear despite intensive study.
This review highlights the need for more detailed analysis of inter-cellular communication pathways to understand the formation of benign corticotroph adenomas and predict novel pharmacological controls.
Current genetic insights leave sporadic corticotroph adenoma management unchanged; leaves open inter-cellular pathways for future target identification.
BACKGROUND: The pathogenesis of tumour formation in the anterior pituitary including adrenocorticotropic hormone (ACTH)-secreting tumours has been intensively studied, but the causative mechanisms involved in pituitary cell transformation and tumourigenesis remain unclear. MATERIALS AND METHODS: We searched PubMed on any paper related with molecular pathology of pituitary corticotroph adenomas and have included to this review all relevant references published up to June 2011. RESULTS: Current studies increased our knowledge on the genetic basis of McCune-Albright syndrome (MAS), multiple endocrine neoplasia type 1 (MEN1), Carney complex (CNC), pituitary adenoma predisposition syndromes and tuberous sclerosis, but they have performed little to elucidate the causes of sporadic pituitary tumours including Cushing disease. DISCUSSION: The aim of this review was to focus on the most recently published advances in the molecular pathology of corticotroph adenomas, which are presented in the context of changes seen in all types of pituitary adenomas, as well as in terms of corticotrophin-releasing hormone/ACTH/cortisol-specific pathways. CONCLUSIONS: We would expect that over the next 5 years, more detailed analysis of inter-cellular communication pathways between pituitary cells, including the cadherins and integrins, and their interactions with other signalling pathways such as the β-catenin cascade will help elucidate what exactly goes awry in the formation of a benign corticotroph adenoma. This should in turn predict novel forms of pharmacological tumour control.
No takes yet. Share an insight, caveat, or question.
Dworakowska et al. (2011) conducted a review in Corticotroph tumours. A review of the molecular pathology of corticotroph adenomas found that while the genetic basis of syndromic pituitary adenomas is better understood, causes of sporadic tumours remain unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: